SBIO
ALPS Medical Breakthroughs ETF
ALPS Medical Breakthroughs ETF is an exchange-traded fund incorporated in the USA. The ETF seeks investment results that correspond generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs Index (ticker symbol: PMBI).
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 138.8 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Dec 30, 2014 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| KYMERA THERAPEUTICS, INC. | 4.2 % |
| MIRUM PHARMACEUTICALS, INC. | 3.4 % |
| CG ONCOLOGY, INC. | 3.4 % |
| ALKERMES PLC | 3.3 % |
| CELCUITY INC. | 3.2 % |
| APELLIS PHARMACEUTICALS, INC. | 3.1 % |
| XENON PHARMACEUTICALS, INC. | 2.9 % |
| APOGEE THERAPEUTICS, INC. | 2.9 % |
| AMICUS THERAPEUTICS INC | 2.7 % |
| CRINETICS PHARMACEUTICALS INC | 2.5 % |
Constituent Breakdown
| Number of holdings | 78 |
| Herfindahl-Hirschman Index | 196 |
| Wgt avg mkt cap (mns) | $2,223 |
| Large cap (>$10bn) | 48.8% |
| Mid cap ($2-10bn) | 35.9% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 89.9% |
| Emerging mkts. | 1.4% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 82.4 % |
 |
IRELAND | 3.3 % |
 |
CHINA | 1.4 % |
 |
BELGIUM | 1.1 % |
 |
BRITAIN | 0.9 % |
 |
GERMANY | 0.8 % |
 |
SWITZERLAND | 0.8 % |
Historical Performance
Standardized Performance (as of 03/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 2.2% | 83.5% | 21.0% | 24.4% | 0.8% | 9.1% | -- | 6.9% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.5% | -- | 0.5% |
| Total Returns | 2.2% | 83.5% | 21.0% | 24.5% | 0.9% | 9.6% | -- | 7.3% | Ann. Volatility | 36.6% | 33.5% | 31.4% | 30.7% | 33.7% | 33.4% | -- | 34.2% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.99 | 32% |
| MSCI EAFE | 1.06 | 32% |
| MSCI Emg Mkts | 0.82 | 25% |
Liquidity Measures
| Avg. volume (000) | 28 |
| ADV traded (mns) | $2 |
| Turnover | 1.1% |
| Avg. Bid/Ask (% of price) | 0.36% |
Technical Indicators
| 30d moving avg. (EMA) | $51.56 |
| Relative strength (RSI) | 56 |
| MACD/Signal | 1.01/0.47 |
| Bollinger Bands (Upper/Lower) | $55.68/$46.40 |
| Short interest (% of AUM) | 1.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. SBIO |
Expenses vs. SBIO |
ALTAR Score™ vs. SBIO |
|---|---|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | 29.8% | -15 bp | +0.1% |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 28.6% | +29 bp | 0.0% |
| BBP | Virtus LifeSci Biotech Products ETF | 21.8% | +29 bp | -3.8% |
| IBRN | iShares Neuroscience and Healthcare ETF | 16.2% | -3 bp | 0.0% |
| CANC | Tema Oncology ETF | 14.4% | +25 bp | -2.0% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 10.9% | -15 bp | -0.9% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 10.3% | +10 bp | -1.2% |
Risk and Returns: SBIO vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/14/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.0%
ALTAR SCORE™
PERCENTILE
AVOID
ETFRC RATING
There are 1,200 funds in the US Equity category with an average
ALTAR Score™ of 5.6% and a standard deviation
of 2.1%. SBIO's ALTAR Score™ is approximately 0.0 standard
deviations above the category average. This places SBIO in the percentile
among funds in the category.
Sell-Side Consensus
$71.04
PRICE TARGET
+29.0%
UPSIDE